Eli Lilly’s weight loss drug, tirzepatide, showed substantial potential in a large Phase 3 study, the results of which were reported on April 28th. If tirzepatide gets approved, it could become a blockbuster. But, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles.
Subscribe to:
Post Comments (Atom)
< + > From Visibility to Automation: The Next Evolution of RTLS in Healthcare
The following is a guest article by HT Snowday, Senior Director at Midmark RTLS A charge nurse trying to determine which patients are re...
No comments:
Post a Comment